Header Logo

Connection

JOHN VIERLING to Adenocarcinoma

Back to Details
This is a "connection" page, showing publications JOHN VIERLING has written about Adenocarcinoma.
JOHN VIERLING
Connection Strength
0.124
Adenocarcinoma
  1. Rusfertide for the treatment of iron overload in HFE-related haemochromatosis: an open-label, multicentre, proof-of-concept phase 2 trial. Lancet Gastroenterol Hepatol. 2023 12; 8(12):1118-1128.
    View in: PubMed
    Score: 0.124
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.